Immatics (NASDAQ:IMTX) Releases Earnings Results, Beats Expectations By $0.51 EPS

Immatics (NASDAQ:IMTX) issued its quarterly earnings data on Thursday. The company reported $0.48 EPS for the quarter, topping the consensus estimate of ($0.03) by $0.51, Zacks reports. The company had revenue of $15.67 million during the quarter, compared to analyst estimates of $16.16 million. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%.

Immatics Price Performance

IMTX stock opened at $4.63 on Friday. The firm has a 50 day simple moving average of $4.96 and a two-hundred day simple moving average of $7.49. The stock has a market cap of $552.62 million, a PE ratio of -7.02 and a beta of 0.83. Immatics has a one year low of $4.06 and a one year high of $13.77.

Institutional Trading of Immatics

A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE boosted its position in Immatics (NASDAQ:IMTX) by 166.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,575 shares of the company’s stock after acquiring an additional 2,231 shares during the quarter. Bank of America Corp DE’s holdings in Immatics were worth $25,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.